Systemic Delivery of Bc12‐Targeting siRNA by DNA Nanoparticles Suppresses Cancer Cell Growth. (16th November 2017)

• Record Type: Journal Article
• Authors: Rahman, Mohammad Aminur; Wang, Pengfei; Zhao, Zhixiang; Wang, Dongsheng; Nannapaneni, Sreenivas; Zhang, Chao; Chen, Zhengjia; Griffith, Christopher C.; Hurwitz, Selwyn J.; Chen, Zhuo G.; Ke, Yonggang; Shin, Dong M.
• Is Part Of: Angewandte Chemie. Volume 129:Number 50(2017)
• Page Start: 16239
• Page End: 16243
• Publication Date: 2017-11-16
• Subjects: Bcl2 -- DNA-Nanotechnologie -- Krebstherapie -- Nanopartikel -- siRNA-Transport; Chemistry -- Periodicals; 540
• DOI: 10.1002/ange.201709485
• Languages: English
• ISSNs: 0044-8249

Abstract

Abstract: Short interfering RNA (siRNA) is a promising molecular tool for cancer therapy, but its clinical success is limited by the lack of robust in vivo delivery systems. Rationally designed DNA nanoparticles (DNPs) have emerged as facile delivery vehicles because their physicochemical properties can be precisely controlled. Nonetheless, few studies have used DNPs to deliver siRNAs in vivo, and none has demonstrated therapeutic efficacy. Herein, we constructed a number of DNPs of rectangular and tubular shapes with varied dimensions using the modular DNA brick method for the systemic delivery of siRNA that targets anti‐apoptotic protein Bcl2. The siRNA delivered by the DNPs inhibited cell growth both in vitro and in vivo, which suppressed tumor growth in a xenograft model that specifically correlated with Bcl2 depletion. This study suggests that DNPs are effective tools for the systemic delivery of therapeutic siRNA and have great potential for further clinical translation.